Bryan Kientz
Nurse Practitioner · Broken Arrow, OKNPI 1912381526
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 279 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$701
- AbbVie$613
- Pfizer$493
- Novo Nordisk$359
- GSK$291
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,378100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $1,025 |
| Lilly USA, LLC | 26 | $701 |
| AbbVie | 47 | $613 |
| Pfizer | 28 | $493 |
| Novo Nordisk | 20 | $359 |
| GSK | 17 | $291 |
| Eisai Inc. | 9 | $286 |
| Bayer | 19 | $223 |
| Amgen | 10 | $206 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $158 |
| Boehringer Ingelheim | 7 | $151 |
| Novartis | 7 | $136 |
| Dexcom, Inc. | 5 | $96 |
| Boston Scientific | 1 | $92 |
| Ardelyx, Inc. | 4 | $80 |
| Abbott | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Philips North America LLC | 2 | $35 |
| Astellas Pharma US Inc | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Exact Sciences | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,378 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 79 | $71,359 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $70,729 |
| MounjaroTirzepatide | 36 | $43,100 |
| EliquisApixaban | 46 | $40,418 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $30,866 |
| OzempicSemaglutide | 20 | $18,638 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $16,116 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $15,349 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $15,200 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $11,776 |
| FarxigaDapagliflozin Propanediol | 17 | $11,688 |
| TradjentaLinagliptin | 14 | $7,243 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $6,459 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,069 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $4,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Tradjenta, Synjardy | $151 | $112,037131 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $291 | $75,798109 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,025 | $45,05667 claims |
| PfizerEliquis, Premarin | $493 | $43,51864 claims |
| Lilly USA, LLCMounjaro | $701 | $43,10036 claims |
| Novo NordiskOzempic | $359 | $18,63820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Other nurse practitioner in Broken Arrow
- Jenny GuthrieTulsa$106K
- Leah MeltonNorman$87K
- Sara GoreOklahoma City$52K
- Teisha GalleglyMoore$43K
- Stacy NewberryTulsa$28K
- Russell RoomsOklahoma City$24K
- Grant YoungOklahoma City$15K
- Monica LawsonNorman$15K
- Amanda SmallTulsa$14K
- Janelle WagnerOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.